IFNG and neoplasm: This analysis indicated that tumor mutation and neoantigen burdens were not associated with PFS, whereas angiogenesis, the T-effector/IFN-γ response, and myeloid inflammatory gene expression signatures were strongly and differentially associated with PFS within and across the treatments [10].